Many rapid improvements 18 years after stroke. Treatment by Edward Tobinick M.D. at the INR in Boca Raton, Florida. Filmed November 29, 2018, 4K version, with subtitles. Text, images and video © 2018, INR PLLC, all rights reserved.

Request a consultation today
Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment is innovative (“off-label”). Terms of Use

Immediate improvement in chronic post-stroke pain 2 years after stroke. Treatment by Edward Tobinick, filmed November 20, 2018, at the INR in Boca Raton. 4K version, with subtitles. Text, images and video © 2018, INR PLLC, all rights reserved.

Request a consultation today
Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment is innovative (“off-label”). Terms of Use

Treatment and filming October 26, 2018, INR Boca Raton, 16 years after stroke. Text, images and video © 2018, INR PLLC, all rights reserved.

Request a consultation today
Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment is innovative (“off-label”). Terms of Use

Treatment and filming October 26, 2018, INR Boca Raton, 16 years after stroke. Text, images and video © 2018, INR PLLC, all rights reserved.

Request a consultation today
Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment is innovative (“off-label”). Terms of Use

Rapid improvement of chronic post-stroke pain at the INR. Perispinal Etanercept Treatment by Edward Tobinick M.D. Text, images and video © 2018, INR PLLC, all rights reserved.

Request a consultation today
Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment is innovative (“off-label”). Terms of Use

News Release, October 8, 2018: The Australian Government will invest $1 million to improve recovery and rehabilitation and help stroke survivors back to work. The Government package includes $750,000 specifically designated for funding a clinical trial of the innovative Perispinal Etanercept Stroke Treatment in Australia. “The project will enable more Australians of working age who have had a stroke to access new innovative and cutting edge treatment options to aid their recovery.”

Perispinal etanercept for treatment of chronic post-stroke neurological dysfunction is a treatment method invented and developed by Edward Tobinick M.D., Medical Director and Founder of the Institute of Neurological Recovery.

More at this link: http://www.health.gov.au/internet/ministers/publishing.nsf/Content/health-mediarel-yr2018-hunt134.htm

The Hon Greg Hunt MP, Minister for Health, Australia

Immediate neurological recovery after treatment at the Institute of Neurological Recovery, September 14, 2018, two years after stroke. Improvements noted in speech, aphasia, apraxia and walking within minutes after treatment at the INR in Boca Raton, Florida.

Request a consultation today
Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment is innovative (“off-label”). Terms of Use

From Kentucky to the INR in Boca Raton, Florida. Published July 16, 2018.

Request a consultation today
Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment is innovative (“off-label”). Terms of Use

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Invited editorial by Edward Tobinick, MD, entitled, “Perispinal etanercept advances as a neurotherapeutic” published in

Expert Review of Neurotherapeutics, on April 25, 2018.

Walking without a stick (cane) after treatment at the INR! Eddie and his family from Scotland, visiting the INR Boca Raton, on April 23, 2018.

Request a consultation today
Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment is innovative (“off-label”). Terms of Use